Subscribe
pharma-istock-598676126-kadmy-
kadmy / iStockphoto.com
22 March 2018Americas

Novartis sues Regeneron over eye treatment

Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea (aflibercept) and Zaltrap (ziv-aflibercept).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis withdraws bid to block US Regeneron imports
4 May 2021   Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.
Big Pharma
GSK buys out Novartis in $13bn consumer healthcare deal
27 March 2018   GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Americas
Novartis withdraws bid to block US Regeneron imports
4 May 2021   Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.
Big Pharma
GSK buys out Novartis in $13bn consumer healthcare deal
27 March 2018   GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

More on this story

Americas
Novartis withdraws bid to block US Regeneron imports
4 May 2021   Pharmaceutical company Novartis has abandoned its attempt to halt US imports of Regeneron’s Eylea pre-filled syringes amid concerns that such a ban could hinder public access to essential treatments.
Big Pharma
GSK buys out Novartis in $13bn consumer healthcare deal
27 March 2018   GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

More features

Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team
AstraZeneca forced to clarify deal terms in row with university
Novartis loses cancer drug patent following Teva challenge at EPO
A step too far? Why Stewart’s approach is dividing opinion
WATCH: Section 112—Where has the dust settled?